Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine... Eur J Nucl Med Mol Imaging (2017) 44:1777–1778 DOI 10.1007/s00259-017-3682-8 LETTER TO THE EDITOR Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 1 1 2 Giovanni Paganelli & Maddalena Sansovini & Emanuela Scarpi Received: 14 March 2017 /Accepted: 15 March 2017 /Published online: 22 March 2017 Springer-Verlag Berlin Heidelberg 2017 Dear Sir, 10 (31%) had a score of 3. Among the 23 FDG PET-negative We would like to thank Zanotti-Fregonara et al. for their in- patients, 12 (52%) showed a score of 4 and 11 (48%) a score teresting letter about our recent study, BLong-term follow-up of 3. Pre-therapy and post-therapy SRI values were and role of FDG PET in advanced pancreatic neuroendocrine concordant. The statistical analysis of our data revealed that the uptake patients treated with 177Lu-DOTATATE^, published in the March 2017 issue [1]. In addition to the positive comments level of SRI was not significant in terms of progression-free on the importance of dual-tracer imaging, Zanotti-Fregonara survival (PFS) and so the SRI uptake value was not included et al. raise the question as to whether the uptake level in in the univariate-multivariate analysis and thus not in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Nuclear Medicine and Molecular Imaging Springer Journals

Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging

Loading next page...
 
/lp/springer_journal/reply-to-predicting-the-outcome-of-peptide-receptor-radionuclide-xYby0YT6DY
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1619-7070
eISSN
1619-7089
D.O.I.
10.1007/s00259-017-3682-8
Publisher site
See Article on Publisher Site

Abstract

Eur J Nucl Med Mol Imaging (2017) 44:1777–1778 DOI 10.1007/s00259-017-3682-8 LETTER TO THE EDITOR Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 1 1 2 Giovanni Paganelli & Maddalena Sansovini & Emanuela Scarpi Received: 14 March 2017 /Accepted: 15 March 2017 /Published online: 22 March 2017 Springer-Verlag Berlin Heidelberg 2017 Dear Sir, 10 (31%) had a score of 3. Among the 23 FDG PET-negative We would like to thank Zanotti-Fregonara et al. for their in- patients, 12 (52%) showed a score of 4 and 11 (48%) a score teresting letter about our recent study, BLong-term follow-up of 3. Pre-therapy and post-therapy SRI values were and role of FDG PET in advanced pancreatic neuroendocrine concordant. The statistical analysis of our data revealed that the uptake patients treated with 177Lu-DOTATATE^, published in the March 2017 issue [1]. In addition to the positive comments level of SRI was not significant in terms of progression-free on the importance of dual-tracer imaging, Zanotti-Fregonara survival (PFS) and so the SRI uptake value was not included et al. raise the question as to whether the uptake level in in the univariate-multivariate analysis and thus not in

Journal

European Journal of Nuclear Medicine and Molecular ImagingSpringer Journals

Published: Mar 22, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off